{"protocolSection":{"identificationModule":{"nctId":"NCT06481098","orgStudyIdInfo":{"id":"HM-OBCT-101"},"organization":{"fullName":"Hanmi Pharmaceutical Company Limited","class":"INDUSTRY"},"briefTitle":"A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-05-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-04-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-09-17","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-05-30","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hanmi Pharmaceutical Company Limited","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects."},"conditionsModule":{"conditions":["Obesity"],"keywords":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","interventionModelDescription":"Part A: single-ascending dose Part B: multiple-ascending dose","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"HM15275","type":"EXPERIMENTAL","description":"Active comparator:\n\nPart A: single-ascending dose\n\nSingle doses of HM15275 in healthy adults administered via subcutaneous injection.\n\nPart B: multiple-ascending dose\n\nMultiple doses of HM15275 in obese adults administered via subcutaneous injection.","interventionNames":["Drug: HM15275","Drug: Placebo of HM15275"]},{"label":"Placebo of HM15275","type":"PLACEBO_COMPARATOR","description":"Placebo comparator:\n\nPart A: single-ascending dose\n\nSingle doses of HM15275 placebo in healthy adults administered via subcutaneous injection.\n\nPart B: multiple-ascending dose\n\nMultiple doses of HM15275 placebo in obese adults administered via subcutaneous injection.","interventionNames":["Drug: HM15275","Drug: Placebo of HM15275"]}],"interventions":[{"type":"DRUG","name":"HM15275","description":"HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.","armGroupLabels":["HM15275","Placebo of HM15275"]},{"type":"DRUG","name":"Placebo of HM15275","description":"A sterile, matching solution supplied in pre-filled syringes.","armGroupLabels":["HM15275","Placebo of HM15275"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: Safety and Tolerability","description":"Number of participants with treatment-emergent adverse events (TEAEs) after a single subcutaneous dose","timeFrame":"Up to Day 29"},{"measure":"Part B: Safety and Tolerability","description":"Number of participants with treatment-emergent adverse events (TEAEs) after multiple subcutaneous doses","timeFrame":"Up to Day 57"}],"secondaryOutcomes":[{"measure":"Part A: Pharmacokinetics","description":"Plasma concentration profile of HM15275 over time after a single subcutaneous dose","timeFrame":"Up to Day 29"},{"measure":"Part B: Pharmacokinetics","description":"Plasma concentration profile of HM15275 over time after multiple subcutaneous doses","timeFrame":"Up to Day 57"}],"otherOutcomes":[{"measure":"Part A: Pharmacodynamics","description":"Change in body weight (kg) from baseline","timeFrame":"Up to Day 29"},{"measure":"Part B: Pharmacodynamics","description":"Change in body weight (kg) from baseline","timeFrame":"Up to Day 57"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Female and male adults, ages ≥ 18 and ≤ 65 years.\n2. Part A: Healthy subjects with body mass index (BMI) ≥ 20.0 kg/m2 and ≤ 27 kg/m2.\n\n   Part B: Obese subjects with BMI ≥ 30.0 kg/m2 and ≤ 45.0 kg/m2 with a stable body weight for 3 months prior to screening (defined as change \\< 5%).\n3. HbA1c \\< 6.5 % \\[based on American Diabetes Association, 2023\\].\n4. Female subjects must be non-pregnant and non-lactating.\n5. Subjects must be able to provide written informed consent and are willing to follow study procedures and commitment to the study duration.\n\nExclusion Criteria:\n\n1. Subject with existence of any surgical or medical condition that, in the judgment of the Investigator, might interfere with the absorption, distribution, metabolism or excretion of the investigational product.\n2. Active or untreated malignancy or has been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for \\< 5 years.\n3. Subjects with a history of any serious adverse reaction or hypersensitivity to study drug components (includes GLP-1, GIP, glucagon analogs) or have contraindicating diseases.\n4. Subjects with confirmed type 1 or type 2 diabetes.\n5. Subject is unwilling to avoid consumption of coffee and caffeine-containing beverages within from 24 hours before each study visit and while subjects are confined to the study center.\n6. Subject is unwilling to abstain from vigorous exercise from 48 hours prior to admission until the Follow-up visit.\n7. History of alcohol abuse as judged by the Investigator within approximately 1 year prior to Screening.\n8. History of regular use (defined as ≥ 10 cigarettes per day) of nicotine-containing products (including but not limited to cigarettes, e-cigarettes, pipe, chewing tobacco, nicotine patch or gum) or vaping products within 6 weeks prior to check-in for the first In-house Period.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Pureun Nam","role":"CONTACT","phone":"+82-10-7476-2057","email":"pureun.nam@hanmi.co.kr"}],"locations":[{"facility":"ProSciento, Inc.","status":"RECRUITING","city":"Chula Vista","state":"California","zip":"91911","country":"United States","contacts":[{"name":"Clinic Answering Service","role":"CONTACT","phone":"619-427-1300"},{"name":"Elaine Watkins, DO, MSPH","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.64005,"lon":-117.0842}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009765","term":"Obesity"}],"ancestors":[{"id":"D000050177","term":"Overweight"},{"id":"D000044343","term":"Overnutrition"},{"id":"D000009748","term":"Nutrition Disorders"},{"id":"D000001835","term":"Body Weight"}],"browseLeaves":[{"id":"M12701","name":"Obesity","asFound":"Obesity","relevance":"HIGH"},{"id":"M26186","name":"Overweight","relevance":"LOW"},{"id":"M25307","name":"Overnutrition","relevance":"LOW"},{"id":"M12684","name":"Nutrition Disorders","relevance":"LOW"},{"id":"M5114","name":"Body Weight","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M21860","name":"Pharmaceutical Solutions","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}